Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iMAGINE: Immunoscore-guided adjuvant chemotherapy and exercise in stage III colon cancer
2020-000401-91Phase 3Terminated
- Sponsor
- Medical University of Vienna
- Start
- May 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oxaliplatin in colon cancer (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Disease-free survival at 3 years. Started May 2020; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2020-000401-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000401-91.